Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 7/20 | 0.47 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3222042 | 0.99 | CRHR1 (0.46) | CRHR1NMT1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3199444 | 0.90 | CRHR1 (0.40) | CRHR1NMT1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3209815 | 0.89 | CRHR1 (0.61) | CRHR1NMT1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3207734 | 0.80 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL3199553 | 0.79 | CRHR1 (0.60) | CRHR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3210548 | 0.79 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL3213993 | 0.78 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL3199789 | 0.78 | CRHR1 (0.50) | CRHR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2056027 | 0.74 | CRHR1 (0.81) | CRHR1 | |
| SCHEMBL2056022 | 0.73 | CRHR1 (0.67) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | claimed |
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2088861-A2 | BENZIMIDAZOLE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008051533-A2 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051533-A2 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | HRH4, SSTR5, CNR1 | CRHR1 4/4885NMT1 3874/4885SLC6A4 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.